when it comes to managing their type 1 diabetes, kids will be kids
Unique clinical burdens for your pediatric patients include:
a need for frequent monitoring and treatment adjustments because of glycemic variability, constant growth, and activity2
difficulty articulating symptoms2
cognitive dysfunction due to daily periods of hypo- and hyperglycemia3
trips to the emergency room due to severe hypo- and hyperglycemia4
with Dexcom, your pediatric patients can be free to be a kid
As the CGM with unparalleled flexibility, Dexcom G7 fits into pediatric patients' lives
![]() for patients 2 years and older | ![]() first-and-only waterproof CGM*,5 |
![]() 30-minute warmup, 2x faster than any other CGM† | ![]() first-and-only CGM with direct connectivity to Apple Watch‡ |
exceptional accuracy in the moments that matter most6
Dexcom defines the gold standard of accuracy5,7

MARD in pediatrics
Dexcom G7
Using Dexcom CGM in young patients with
type 1 diabetes can lead to:
![]() | reduced hypoglycemic events by | ![]() | increased time in range by within 8 weeks |

a clear connection: Dexcom-powered AID leads to improved outcomes12-14
2 Real-world studies put Dexcom CGM to the test


caring for a child with type 1 diabetes can be overwhelming-
give your caregivers peace of mind with Dexcom G715
Dexcom CGM offers multiple features to help protect your pediatric patients:
![]() | Urgent Low Soon | ![]() | 12-hour grace period |
![]() | Delay First High Alert | ![]() | Rise rate |
![]() | Dexcom Follow‡‡ | ![]() | Fall rate |
![]() | When used to share glucose data with one or more followers, Dexcom Follow is associated with16: |
![]() | lower mean glucose | ![]() | more time spent in range |
![]() | less time in hyper- and hypoglycemia | ![]() | significantly higher CGM utilization |
get your patients started for free today
Easily check Dexcom's formulary coverage in your area
AID = automated insulin delivery; CGM = continuous glucose monitoring; CIQ = Control-IQ Technology; CLIO = Control-IQ Observational; DKA = diabetic ketoacidosis; MARD = mean absolute relative difference; TIR = time in range.
*The Dexcom G7 Sensor is water-resistant and may be submerged under 8 feet of water for up to 24 hours without failure when properly installed. †Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. ‡Smart device sold separately. To view a list of compatible devices, visit dexcom.com/compatibility. §In very young children (aged 2-7 years). ||Results obtained with a previous generation Dexcom CGM system and are applicable to G6/G7 given similar feature sets and better performance and usability. ¶In adolescents (aged 16-24 years). #Adverse events were reported monthly over 12 months and were compared to historical data from the T1D Exchange. Patient-reported outcomes were assessed quarterly. All study visits were virtual. **N=9028 using the time-weighted average target of 110 mg/dL. ††Hypoglycemia consensus target of <4% time below 70 mg/dL. ‡‡Separate Follow app and internet connection required.
1 Dexcom, Data on File, 2025. 2 Streisand R, et al. Curr Diab Rep. 2014;14(9):520. 3 Gonder-Frederick LA, et al. Diabetes Care. 2009;32(6):1001-1006. 4 Mulinacci G, et al. Diabetes Technol Ther. 2019;21(1):6-10. 5 Dexcom G7 User Guide, 2023. 6 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K213919. Published December 7, 2022. 7 FreeStyle Libre 3 User Guide. 8 DiMeglio LA, et al. Diabetes Care. 2021;44(2):464-472. 9 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-147. 10 Thabit H, et al. Diabetes Care. 2020;43(10):2537-2543. 11 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K222447. Published March 3, 2023. https://www.accessdata.fda.gov/cdrh_docs/reviews/K222447.pdf. 12 Graham R, et al. Diabetes Technol Ther. 2024;26(1):24-32. 13 Breton MD, et al. Diabetes Technol Ther. 2021;23(9):601-608. 14 Forlenza GP, et al. Diabetes Technol Ther. 2024;26(8):514-525. 15 Polonsky WH, et al. J Diabetes Sci Technol. 2022;16(1):97-105. 16 Welsh JB, et al. Diabetes Ther. 2019;10(2):751-755.